Currently Enrolling Clinical Trials
Sitravatinib (MGCD516)
Sponsored by Mirati
Study 516-002:
Phase 2 study of sitravatinib in combination with nivolumab for clear cell renal cell cancer
Phase 2 neoadjuvant clinical trial of sitravatinib in combination with nivolumab in patients with clear cell renal cell cancer
Study 516-003:
Phase 2 study of sitravatinib in combination with a checkpoint inhibitor for urothelial carcinoma
Phase 2 clinical trial of sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma
Study 516-005:
Phase 3 study of sitravatinib in combination with nivolumab for non-small cell lung cancer (NSCLC) (SAPPHIRE)
Phase 3 pivotal trial of sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy
Study 516-008:
Phase 1/1b study of sitravatinib in combination with nivolumab and ipilimumab
Study of sitravatinib in combination with nivolumab and ipilimumab in patients with advanced or metastatic clear cell renal cell carcinoma or other solid malignancies
Sitravatinib collaborative trials are run by BeiGene and Bristol Myers Squibb, respectively.
KRAS G12C Inhibitor Adagrasib (MRTX849)
Sponsored by Mirati
Study 849-001:
Phase 1/2 study of MRTX849 in patients with cancer having a KRASG12C mutation (KRYSTAL-1)
Phase 1b/2 clinical trial of single agent MRTX849 and in combinations in patients with advanced solid tumors that have a KRASG12C mutation. Combination cohorts include adagrasib with cetuximab, afatinib or pembrolizumab
Study 849-002:
Phase 1/2 study of MRTX849 in combination with TNO-155 in patients with cancer having a KRASG12C mutation (KRYSTAL-2)
Phase 1b/2 clinical trial of MRTX849 in combination with TNO155—a selective, orally bioavailable allosteric inhibitor of wild-type SHP2—in patients with a KRASG12C mutation
Study 849-007:
Phase 2 study of MRTX849 in combination with pembrolizumab in NSCLC patients having a KRASG12C mutation (KRYSTAL-7)
Phase 2 clinical trial of MRTX849 in combination with pembrolizumab in patients with advanced NSCLC with a KRASG12C mutation stratified by TPS score
Study 849-010:
Phase 3 study of MRTX849 with cetuximab vs chemotherapy in patients with CRC with KRASG12C mutation (KRYSTAL-10)
Randomized Phase 3 clinical trial comparing MRTX849 in combination with cetuximab versus chemotherapy in patients with advanced colorectal cancer with KRASG12C mutation in the second-line setting
Study 849-012:
Phase 3 study of MRTX849 vs docetaxel in patients with NSCLC with KRASG12C mutation (KRYSTAL-12)
Randomized Phase 3 clinical trial of MRTX849 versus docetaxel in patients with previously treated non-small cell lung cancer with KRASG12C mutation
Study 849-014:
A Phase 1/1b study of MRTX849 in combination with BI 1701963 in patients with advanced solid tumors with KRASG12C mutation (KRYSTAL-14)
Phase 1/1b clinical trial of MRTX849 in combination with BI 1701963 in patients with advanced solid tumors with KRASG12C mutation
Adagrasib collaborative trials are run by Zai Lab, Sanofi, Novartis, Boehringer Ingelheim, respectively.
MTA-Cooperative PRMT5 Inhibitor (MRTX1719)
Sponsored by Mirati
Study 1719-001:
Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Phase 1/2, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can decide if a specific medicine is the correct treatment for a particular patient or whether enrollment in a clinical trial is appropriate. If you have questions about treatment of your medical condition, consult a qualified healthcare professional.
To identify clinical trials that match your diagnosis, treatment history and location, call 1-844-893-5530 or use our online Study Locator